Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Summary

This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2009-04-20

Primary completion

2017-05-19

Completion

2017-05-19

Drugs

Indications